Non-surgical management of cystic prolactinomas

B. Bahuleyan, G. Menon, S. Nair, B.R.M. Rao, H.V. Easwer, K. Krishna

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50% of the tumour volume; (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6%, visual deficits in 50% and headache in 50% of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50% of patients had hormonal cure, 50% had radiological cure and 50% had reduction in the size of the tumour. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery. © 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)1421-1424
Number of pages4
JournalJournal of Clinical Neuroscience
Volume16
Issue number11
DOIs
Publication statusPublished - 2009

Fingerprint

Prolactinoma
Dopamine Agonists
Bromocriptine
Erectile Dysfunction
Tumor Burden
Prolactin
Headache
Cysts
Therapeutics
Serum

Cite this

Bahuleyan, B., Menon, G., Nair, S., Rao, B. R. M., Easwer, H. V., & Krishna, K. (2009). Non-surgical management of cystic prolactinomas. Journal of Clinical Neuroscience, 16(11), 1421-1424. https://doi.org/10.1016/j.jocn.2009.03.024
Bahuleyan, B. ; Menon, G. ; Nair, S. ; Rao, B.R.M. ; Easwer, H.V. ; Krishna, K. / Non-surgical management of cystic prolactinomas. In: Journal of Clinical Neuroscience. 2009 ; Vol. 16, No. 11. pp. 1421-1424.
@article{7d1f621e964b40d3b58ab904d2d88a52,
title = "Non-surgical management of cystic prolactinomas",
abstract = "Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50{\%} of the tumour volume; (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6{\%}, visual deficits in 50{\%} and headache in 50{\%} of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50{\%} of patients had hormonal cure, 50{\%} had radiological cure and 50{\%} had reduction in the size of the tumour. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery. {\circledC} 2009 Elsevier Ltd. All rights reserved.",
author = "B. Bahuleyan and G. Menon and S. Nair and B.R.M. Rao and H.V. Easwer and K. Krishna",
note = "cited By 5",
year = "2009",
doi = "10.1016/j.jocn.2009.03.024",
language = "English",
volume = "16",
pages = "1421--1424",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "11",

}

Bahuleyan, B, Menon, G, Nair, S, Rao, BRM, Easwer, HV & Krishna, K 2009, 'Non-surgical management of cystic prolactinomas', Journal of Clinical Neuroscience, vol. 16, no. 11, pp. 1421-1424. https://doi.org/10.1016/j.jocn.2009.03.024

Non-surgical management of cystic prolactinomas. / Bahuleyan, B.; Menon, G.; Nair, S.; Rao, B.R.M.; Easwer, H.V.; Krishna, K.

In: Journal of Clinical Neuroscience, Vol. 16, No. 11, 2009, p. 1421-1424.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Non-surgical management of cystic prolactinomas

AU - Bahuleyan, B.

AU - Menon, G.

AU - Nair, S.

AU - Rao, B.R.M.

AU - Easwer, H.V.

AU - Krishna, K.

N1 - cited By 5

PY - 2009

Y1 - 2009

N2 - Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50% of the tumour volume; (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6%, visual deficits in 50% and headache in 50% of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50% of patients had hormonal cure, 50% had radiological cure and 50% had reduction in the size of the tumour. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery. © 2009 Elsevier Ltd. All rights reserved.

AB - Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50% of the tumour volume; (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6%, visual deficits in 50% and headache in 50% of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50% of patients had hormonal cure, 50% had radiological cure and 50% had reduction in the size of the tumour. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery. © 2009 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.jocn.2009.03.024

DO - 10.1016/j.jocn.2009.03.024

M3 - Article

VL - 16

SP - 1421

EP - 1424

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 11

ER -